Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Altimmune, Inc. has received a consensus rating of "Moderate Buy" from eight brokerages, with five brokers issuing buy ratings and a target price averaging $18.20.
• The company reported ($0.26) earnings per share in its last quarterly results, beating analysts' estimates, but it continues to face significant challenges including a negative net margin of 451,200.00%.
• Significant institutional investment activity includes GAMMA Investing raising its holdings in Altimmune by 214.2%, reflecting growing institutional interest in the stock.

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $18.20.

Several equities research analysts have recently weighed in on ALT shares. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research note on Friday, June 27th. JMP Securities decreased their target price on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a research note on Thursday, July 10th. Wall Street Zen downgraded shares of Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. Finally, The Goldman Sachs Group upgraded shares of Altimmune to a "strong sell" rating in a research note on Thursday, July 10th.

Altimmune Price Performance

Shares of ALT opened at $4.08 on Friday. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16. The stock has a market cap of $330.92 million, a PE ratio of -3.24 and a beta of 0.47. The firm has a fifty day moving average price of $5.33 and a 200 day moving average price of $5.62.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative net margin of 451,200.00% and a negative return on equity of 65.44%. The firm had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. During the same period in the previous year, the company earned ($0.34) earnings per share. As a group, equities analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock worth $34,000 after purchasing an additional 4,598 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new position in Altimmune during the second quarter worth about $40,000. Magnus Financial Group LLC purchased a new position in Altimmune during the first quarter worth about $50,000. Headland Capital LLC purchased a new position in Altimmune during the first quarter worth about $50,000. Finally, Geneos Wealth Management Inc. purchased a new position in Altimmune during the first quarter worth about $50,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.